Rheumatology

Treating the inflammation of rheumatoid arthritis early leads to less disability and improved patient outcomes.

The licensing of biosimilars heralds the start of a new era for physicians treating immune and inflammatory diseases.

Biosimilars have been available in Europe since 2006, and biosimilars of monoclonal antibodies since 2013, and are now a widespread clinical reality.

Rheumatosphere is an initiative started in Glasgow, UK, in 2012; its aim is to raise awareness about arthritis and arthritis-related research.

The symposium at the EULAR 2017 congress aimed to provide insights into the burden of psoriatic arthritis on patients’ daily lives, including the…

Understanding the interplay between the immune system and gastrointestinal tract microbiota is an evolving area of research.

Immunisation of biological drugs can result in reduced efficacy of treatment and an increased risk of adverse effects.

Uveitis is an inflammatory disease with significant disease burden, as it causes ≤10% of legal blindness in the USA.